Our #Opal bone marrow image is featured on the new @BloodPortfolio cover, highlighting the discovery of OSMR as a novel #AML biomarker. This work was led by @HusseinAbbasLab, @patrickreville, @BofeiWang3 and @JenMarvinPeek at @MDAndersonNews. Learn more: https://t.co/VzHz9edftU

New paper, we used spectral flow cytometry panels to characterize AML and T cells. @HusseinAbbasLab Comprehensive Profiling of AML and T Cell States Across Disease Stages in Acute Myeloid Leukemia Using Spectral Flow Cytometry https://t.co/QLIZePVRBB

Huge props to Chris Ly, @iveletic and the whole team after a ton of trial-and-error, to perform high-throughput spatial CyTof and Lunaphore on bone marrow samples in AML. Just the beginning of this proof-of-concept work.

➡️ Excited to share the phase 1b/2 clin trial of Aza-Ven-Magro in ND high-risk & R/R AML from @MDAndersonNews led by @Daver_Leukemia, just out in @CCR_AACR ✅ Interesting correlative analysis by @HusseinAbbasLab interrogating mech of Magro resistance in TP53-mut AML ✅Despite

🙂 Very Happy to share this comprehensive review on AML, from an @MDAndersonNews perspective, discussing all that is new and exciting in the field 🩸 @DrHKantarjian ➡️ Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges @AcsCancer

Over the past year, I've grown special interest in caring for patients with #SystemicMastocytosis and transformed my clinic to almost exclusively seeing SM patients. Research focus also transforming. Common theme is that these patients spend years frustrated before they are

Featured on the new journal cover: Single-Cell CD4 and CD8 T-Cell Secretome Profiling Reveals Temporal and Niche Differences in Acute Myeloid Leukemia Following Immune Checkpoint Blockade Therapy https://t.co/ZUfQhhOriR @HusseinAbbasLab @Daver_Leukemia @patrickreville

Stem cell-like states confer poor outcomes in blood cancer—but what mechanisms drive this and how can they be therapeutically targeted? In our new preprint, we show how a single TF represses one enhancer to maintain a subset of high-risk leukemias: 🧵👇 https://t.co/JS8yUt0hCJ

DOD grant on TP53 AML was awarded!! Back to my graduate school roots. Important to realize that i had 7 unfunded DOD applications over past 3 years that preceded this successful one. Learnt a lot from reviewers’ comments. #KeepItReal #LeukemiaResearch @MDAndersonNews

Glad to see the work from the lab being featured. @BofeiWang3 @patrickreville spearheaded this effort. We hope furthering this work can translate into better treatments for AML patients. More to come From @HusseinAbbasLab . @MDAndersonNews

Very Proud of @BofeiWang3. Joined as a postdoc in Jan 2022. Now with numerous papers, contributions to grants, and now awarded the Endowed Fellowship for Research Excellence in Leukemia Research at MDA. Driven, motivated, hardworking #RightAttitude. Congrats. @MDAndersonNews

When in @unibern you bike your way through the hospital tunnels. A fun experience. Great hospitality by Prof Adrian Ochsenbein and his colleagues. Thanks for hosting me and discussing collaborations

What are the latest advances in single cell profiling? Our Dr. Abbas Hussein outlined five applications of this technology. @HusseinAbbasLab @AACR #AACR24 #EndCancer

Poster sessions at @AACR are great opportunities to identify potential collaborators and have direct FaceTime with researchers to exchange ideas and contacts. Something I appreciate more and more with every annual meeting.

Great time at @AACR Annual meeting. Plenary talks by Aviv Regev and Jakob Kather yesterday had deep insights into application of AI/DL/LLM in patient care.

@MDAndersonNews Miscalculation, was in my third year of fellowship.!

This underscores the significant impact of smaller grants by $, especially for *junior faculty*, that can have impact for new ideas. Deep gratitude to LLL for their dedication to leukemia research and their faith in our work in the South over the decades. @MDAndersonNews

As a 1st-year med-onc fellow in 2020, I received the Ladies Leukemia League (LLL) grant. Despite its modest sum (~$30K), it was pivotal for my research and securing further funding. Fast forward to 2024, LLL once again believed in a new idea of mine, uniquely funding it.

Another story from the lab fresh in the press! Studying B cells and their repertoires; the unsung players in AML. Kudos to the team work and collaborative efforts. @patrickreville @DapengHao Nance and @GopiSMohan. @MDAndersonNews

Another exciting milestone. @BofeiWang3 and @patrickreville beautifully describe IFNg impact in AML’s venetoclax resistance and immune evasion. Now published in @NatureComms. @MDAndersonNews . More to come from our lab!